Status:
UNKNOWN
Contrast-Enhanced Ultrasound Ability in the Characterization of Ovarian Masses
Lead Sponsor:
University Hospital, Tours
Conditions:
Ovarian Tumor
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
This study intends to assess the ability of contrast-enhanced ultrasound in the detection of benign and malignant ovarian masses compared to unenhanced ultrasound. By using an intravascular contrast ...
Detailed Description
SonoVue (Sulphur hexafluoride microbubbles) is a microbubbles preparation that is stable, resistant to pressure and specifically designed to be used as a contrast agent for ultrasound imaging. Study ...
Eligibility Criteria
Inclusion
- 18 years of age or older
- Patient with adnexal mass detected by ultrasound
- Any programmed surgery
Exclusion
- Any contraindication to surgery
- Injection of another contrast agent within 24 hours before the study examination
- Pregnancy, breastfeeding
- Patient known to have a coronary syndrome
- Unstable angina and myocardial infarction
- Acute cardiac failure, Class III/IV cardiac failure
- Severe rhythm disorders
- Acute endocarditis
- Prosthetic valves
- Patient previously having received an investigational drug within 30 days prior to admission into this study
Key Trial Info
Start Date :
September 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2009
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00248820
Start Date
September 1 2002
End Date
February 1 2009
Last Update
November 22 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Tours
Tours, France, 37044